If you have ever tried to bring a medicine to market in Hong Kong and found yourself buried in a labelling checklist that seems to grow longer every time you look at it — you are not alone. Pharmaceutical labelling and packaging requirements in Hong Kong are genuinely detailed, and getting them wrong is not a minor administrative inconvenience. It is a registration delay, a product recall, or a regulatory enforcement action waiting to happen.
The good news is that once you understand the framework — who sets the rules, what they require, and where the common pitfalls are — the path becomes considerably clearer. Here is a structured, data-informed breakdown of everything you need to know about pharmaceutical labelling and packaging requirements in Hong Kong.
🏛️ The Regulatory Framework: Who Sets the Rules
Pharmaceutical labelling and packaging in Hong Kong is governed primarily by the Pharmacy and Poisons Ordinance (Cap. 138) and its subsidiary legislation — the Pharmacy and Poisons Regulations — administered by the Pharmacy and Poisons Board of Hong Kong (PPB). The Department of Health’s Drug Office serves as the operational arm responsible for the day-to-day administration of pharmaceutical product registration and compliance.
All pharmaceutical products sold in Hong Kong must be registered under the Drug Registration Scheme before they can be legally placed on the market. As of 2025, the Drug Office maintains a registered pharmaceutical product database of over 14,000 registered pharmaceutical products, spanning prescription-only medicines, pharmacy-only medicines, and general sale medicines — each category carrying its own distinct labelling obligations.
The PPB’s labelling requirements are substantively aligned with international standards — particularly those of the International Council for Harmonisation (ICH) and the World Health Organisation (WHO) guidelines on pharmaceutical labelling — but with Hong Kong-specific requirements that must be addressed independently of any other market’s labelling package.
📋 Core Labelling Requirements: What Must Appear on Every Pack
The foundational labelling requirements for registered pharmaceutical products in Hong Kong are set out in the Pharmacy and Poisons Regulations. Every pharmaceutical product label — both the immediate container label and the outer packaging label — must include a defined set of mandatory information elements.
The Mandatory Label Elements
Product Identity Information:
- The approved name of the product — the name under which the product is registered with the PPB
- The International Non-proprietary Name (INN) of each active ingredient, expressed in English
- The strength of each active ingredient per dosage unit, expressed in standard pharmacopoeial units
- The pharmaceutical form — tablet, capsule, solution for injection, topical cream, and so forth
Manufacturer and Registration Information:
- The name and address of the manufacturer responsible for the finished product
- The name and address of the local registration holder — the Hong Kong-registered entity that holds the product registration certificate
- The Hong Kong product registration number — the unique identifier assigned by the Drug Office upon successful registration, in the format HK-XXXXX
Batch and Traceability Information:
- The batch number or lot number, enabling full traceability through the manufacturing and distribution chain
- The manufacturing date or, where applicable, the date of filling for sterile products
- The expiry date, expressed in a format that is unambiguous to the end user — month and year at minimum, with day-month-year required for products with a shelf life of less than three months
Storage and Handling Information:
- Storage conditions, expressed in specific temperature and humidity parameters where relevant — not merely “store in a cool, dry place” but the actual defined conditions under which the product’s stability has been established
- Special handling precautions where applicable — including light-sensitive storage requirements, refrigeration requirements, and freeze-avoidance requirements for biological products
Usage and Safety Information:
- Dosage instructions appropriate to the product’s approved indications and target patient population
- Contraindications and warnings relevant to the product’s safety profile
- “Keep out of reach of children” statement — a mandatory requirement for all pharmaceutical products regardless of category
🌐 The Language Requirement: English and Chinese
One of the most operationally significant labelling requirements in Hong Kong — and one that catches many international manufacturers off guard — is the bilingual labelling requirement.
All pharmaceutical product labels in Hong Kong must carry the mandatory information elements in both English and Traditional Chinese. This is not optional, and it is not satisfied by providing a separate Chinese-language insert. The bilingual content must appear on the label itself.
This requirement has direct implications for label design and packaging engineering. A label that is designed for a single-language market — whether that is a European market using English only or a Japanese market using Japanese only — will almost certainly require complete redesign for Hong Kong registration. The bilingual requirement effectively doubles the text content that must be accommodated within the label space, which has significant implications for font size, label dimensions, and overall packaging design.
For products with small immediate containers — single-dose ampoules, small-volume vials, or blister strips — the bilingual requirement can create genuine label space challenges that require creative packaging engineering solutions, including the use of peel-off labels, booklet labels, or outer packaging that carries the full bilingual information while the immediate container label carries a defined minimum subset.
The Drug Office’s guidance on minimum label content for small containers specifies that where space constraints make full bilingual labelling impractical on the immediate container, the immediate container label must carry at minimum:
- The product name
- The active ingredient(s) and strength(s)
- The batch number
- The expiry date
- The storage conditions
With the full bilingual label content carried on the outer packaging.
💊 Prescription-Only vs. Non-Prescription: Category-Specific Requirements
Hong Kong’s pharmaceutical classification system — established under the Pharmacy and Poisons Ordinance — creates three principal categories of pharmaceutical product, each with distinct labelling obligations.
Prescription-Only Medicines (Part I Poisons and Schedule 1 Antibiotics)
Prescription-only medicines in Hong Kong must carry the statement “To be sold only against a registered medical practitioner’s prescription” prominently on the label. This statement must appear in both English and Traditional Chinese and must be positioned to ensure it is clearly visible to the dispensing pharmacist and the end patient.
Additionally, prescription-only medicines that fall within the Dangerous Drugs Ordinance (Cap. 134) — covering controlled substances including opioid analgesics, benzodiazepines, and certain stimulants — carry additional labelling requirements under that ordinance, including specific warnings and the requirement for dispensing labels that identify the prescribing practitioner and the dispensing pharmacy.
Pharmacy-Only Medicines (Part II Poisons)
Pharmacy-only medicines must carry the statement “To be dispensed only by or under the supervision of a registered pharmacist” on the label, again in both English and Traditional Chinese. These products may be sold without a prescription but only through registered pharmacies under pharmacist supervision.
General Sale Medicines
General sale medicines — products that may be sold through retail outlets other than registered pharmacies — carry the least restrictive labelling requirements but must still comply with all mandatory label element requirements and the bilingual language requirement.
📦 Packaging Requirements: Beyond the Label
Pharmaceutical packaging requirements in Hong Kong extend beyond label content to the physical packaging itself. The Drug Office’s registration requirements specify that the packaging submitted for registration must be the packaging that will be used for the marketed product — any subsequent packaging change requires a variation application to the PPB.
Child-Resistant Packaging
Child-resistant packaging is required for pharmaceutical products that present a significant risk of harm to children in the event of accidental ingestion. The specific products for which child-resistant packaging is mandated include:
- Oral solid dosage forms containing iron at doses above defined thresholds
- Products containing aspirin or paracetamol in quantities above defined pack size thresholds
- All liquid oral preparations containing more than 25% ethanol by volume
- Products containing substances classified as very toxic or toxic under Hong Kong’s chemical classification framework
Child-resistant packaging used for Hong Kong-registered pharmaceutical products must meet the performance standards of ISO 8317 — the international standard for child-resistant packaging — or an equivalent standard accepted by the Drug Office.
Tamper-Evident Packaging
While Hong Kong does not currently mandate tamper-evident packaging for all pharmaceutical categories as a standalone regulatory requirement, the Drug Office’s good manufacturing practice (GMP) guidelines — aligned with the PIC/S Guide to GMP — effectively require tamper-evident features for products where tamper evidence is considered a patient safety necessity. In practice, this means that most oral solid dosage forms, liquid preparations, and sterile products marketed in Hong Kong incorporate tamper-evident packaging features as a matter of standard pharmaceutical manufacturing practice.
📊 The Cost of Getting It Wrong: Enforcement and Recall Data
The regulatory consequences of non-compliant pharmaceutical labelling in Hong Kong are not theoretical. The Drug Office publishes regular enforcement actions and product recall notices — and labelling non-compliance is a consistent feature of the enforcement landscape.
Between 2020 and 2024, the Drug Office issued over 340 product recall notices, of which approximately 28% — nearly one in three — involved labelling or packaging deficiencies as a primary or contributing cause. These included:
- Missing or incorrect batch number or expiry date information — the single most common labelling deficiency identified in recall notices
- Incorrect or missing storage condition information, particularly for cold-chain products where incorrect storage labelling had led to product being stored outside its validated temperature range
- Incomplete bilingual labelling — products where the Traditional Chinese translation was absent, incomplete, or contained translation errors that materially affected the safety information conveyed to patients
- Non-compliant product registration number format or the use of a registration number that did not correspond to the registered product formulation or strength
The financial consequences of a labelling-driven product recall are substantial. Industry data suggests that the average direct cost of a pharmaceutical product recall in the Asia-Pacific region — covering logistics, destruction, regulatory notification, and replacement supply — ranges from $800,000 to $4.2 million per recall event, depending on product volume and distribution reach. The reputational and regulatory relationship costs are considerably harder to quantify but are consistently identified by pharmaceutical executives as the more significant long-term consequence.
🔍 Recent Developments: Digital Labelling and QR Code Integration
One of the most significant recent developments in Hong Kong pharmaceutical labelling practice is the progressive integration of QR codes and digital labelling elements into pharmaceutical packaging.
The Drug Office has not yet established a formal regulatory framework for digital labelling as a replacement for physical label content — all mandatory label elements must still appear in physical printed form on the label. However, the use of QR codes as a supplementary information channel — linking to full prescribing information, patient information leaflets, and product-specific safety communications — is increasingly common in Hong Kong pharmaceutical packaging and is not prohibited by current regulations provided the physical label carries all mandatory elements in full.
The European Medicines Agency’s progressive development of the ePI (electronic Product Information) framework — which is moving towards formal regulatory acceptance of electronic product information as a complement to physical labelling — is being closely monitored by the Drug Office as a potential model for future Hong Kong regulatory development in this area.
💡 Practical Implications for International Manufacturers
For international pharmaceutical manufacturers seeking Hong Kong registration, the labelling and packaging requirements carry several practical implications that are worth addressing explicitly.
Start the bilingual translation process early. Professional pharmaceutical translation from English to Traditional Chinese — particularly for complex clinical and pharmacological content — takes time and requires specialist translators with pharmaceutical domain expertise. Translation errors in safety-critical label content are a registration risk and a patient safety risk simultaneously.
Design your Hong Kong label as a standalone exercise. Do not assume that your EU, UK, Australian, or Japanese label can be adapted for Hong Kong with minor modifications. The bilingual requirement, the HK registration number format, and the specific mandatory statement requirements for each product category mean that Hong Kong labelling is effectively a fresh design exercise.
Build packaging change management into your post-registration compliance programme. Any change to approved labelling or packaging after registration requires a variation application — and the Drug Office’s variation classification guidelines determine whether the change requires prior approval before implementation or can be notified post-implementation. Getting this wrong — implementing a packaging change without the required prior approval — is a compliance breach that can trigger enforcement action.
The Bottom Line
Pharmaceutical labelling and packaging requirements in Hong Kong are detailed, bilingual, and category-specific — and the consequences of non-compliance range from registration delays to product recalls with costs running into millions of dollars. But they are also well-documented, consistently administered, and navigable with the right expertise and preparation.
The companies that get Hong Kong labelling right are the ones that treat it as a standalone regulatory exercise from the outset — not an afterthought to be addressed after the registration dossier is otherwise complete. In a market where nearly one in three product recalls involves a labelling or packaging deficiency, the investment in getting the label right the first time is one of the most straightforward risk management decisions a pharmaceutical company can make.
